Top Banner
PIM & QRD MONICA BUCH MONICA BUCH Scientific Administrator European Medicines Agency DIA European Regulatory Affairs Forum 2010 June 1-2 2010 June 1 2, 2010 London
24

European Medicines Agency - diaglobal.org monica buch.pdf · PIM & QRD MONICA BUCHMONICA BUCH Scientific Administrator European Medicines Agency DIA European Regulatory Affairs Forum

Dec 24, 2018

Download

Documents

dodat
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: European Medicines Agency - diaglobal.org monica buch.pdf · PIM & QRD MONICA BUCHMONICA BUCH Scientific Administrator European Medicines Agency DIA European Regulatory Affairs Forum

PIM & QRD

MONICA BUCHMONICA BUCHScientific AdministratorEuropean Medicines Agency

DIA European Regulatory Affairs

Forum 2010June 1-2 2010June 1 2, 2010

London

Page 2: European Medicines Agency - diaglobal.org monica buch.pdf · PIM & QRD MONICA BUCHMONICA BUCH Scientific Administrator European Medicines Agency DIA European Regulatory Affairs Forum

Disclaimer

The views and opinions expressed in the following PowerPoint slidesare those of the individual presenter and should not be attributed toDrug Information Association, Inc. (“DIA”), its directors, officers,employees, volunteers, members, chapters, councils, Special InterestA C iti ffili t i ti ith hi h thArea Communities or affiliates, or any organization with which thepresenter is employed or affiliated.

These PowerPoint slides are the intellectual property of the individualpresenter and are protected under the copyright laws of the UnitedStates of America and other countries. Used by permission. All rights

d D I f ti A i ti DIA d DIA lreserved. Drug Information Association, DIA and DIA logo areregistered trademarks or trademarks of Drug Information AssociationInc. All other trademarks are the property of their respective owners.

2www.diahome.orgDrug Information Association

Page 3: European Medicines Agency - diaglobal.org monica buch.pdf · PIM & QRD MONICA BUCHMONICA BUCH Scientific Administrator European Medicines Agency DIA European Regulatory Affairs Forum

PIM - Overview

• Introduction to PIMWhat PIM isPIM Systems

• Status of PIMPilot PhaseData Migration

• Plans and challengesPlans and challengesOpportunities and challenges for MAHsThe way forward

Drug Information Association www.diahome.org 3

Page 4: European Medicines Agency - diaglobal.org monica buch.pdf · PIM & QRD MONICA BUCHMONICA BUCH Scientific Administrator European Medicines Agency DIA European Regulatory Affairs Forum

What is PIM

• PIM (Product Information Management) isPIM (Product Information Management) is a system for the electronic exchange of product informationproduct information

• New marketing authorisation applications and post authorisation submissions in theand post-authorisation submissions in the centralised procedure

• Compliant with the Quality Review of Documents (QRD) templates

Drug Information Association www.diahome.org 4

Page 5: European Medicines Agency - diaglobal.org monica buch.pdf · PIM & QRD MONICA BUCHMONICA BUCH Scientific Administrator European Medicines Agency DIA European Regulatory Affairs Forum

PIM Systems

Applicant Regulator

DataExchangeStandard

AuthorAmend

ReviewComment

Standard(DES)

2.7

T i i i E d li kTranslateCo e tApprove

LAT PRSPDVE

Transmission via Eudralink

ProprietaryTool

Key : LAT = Light Authoring ToolPDVE = PIM DES Validation EnginePRS PIM R i S t

Drug Information Association www.diahome.org 5

PRS = PIM Review System

Page 6: European Medicines Agency - diaglobal.org monica buch.pdf · PIM & QRD MONICA BUCHMONICA BUCH Scientific Administrator European Medicines Agency DIA European Regulatory Affairs Forum

PIM Systems

Data Exchange Standard (DES) v2.8• Driven by regulatory and business requirements

Implement readability changes to the package leafletImplement readability changes to the package leafletSupport non-conflicting overlapping comments

• Release for testing technical changes while• Release for testing technical changes while waiting for package leaflet text

Will b t d b PIM R i S t 6 d• Will be supported by PIM Review System v6 and used for the migration exercise

Drug Information Association www.diahome.org 6

Page 7: European Medicines Agency - diaglobal.org monica buch.pdf · PIM & QRD MONICA BUCHMONICA BUCH Scientific Administrator European Medicines Agency DIA European Regulatory Affairs Forum

PIM Systems

PIM Review System (PRS) v6Objective ProgressImprove the PRS

f d• Issues identified and new architecture to remedy issues

performance and scalability

• Build started, interim load test to confirm new architecture

Improve the usability f th PRS

• New user interface being designed with user interface t dof the PRS experts and user group

• Main pages redesigned and approved by the user group

Improve the PRS New algorithm selected and being implemented with userImprove the PRS document compare

New algorithm selected and being implemented with user involvement

Provide all high priority requirements

High priority requirements for PRS 6.0 being implemented

Drug Information Association www.diahome.org 7

priority requirements

Page 8: European Medicines Agency - diaglobal.org monica buch.pdf · PIM & QRD MONICA BUCHMONICA BUCH Scientific Administrator European Medicines Agency DIA European Regulatory Affairs Forum

PIM Status

Pilot PhaseType No.

• 5 companies participating• 7 products

4 MAA

Type No.Initial MAA 4Migration 3

• 4 MAAs• 3 migrations• 26 PAPs

Line Extension 1Renewal 2Annual Reassessment 1

Issues encounteredTechnical (DES) and systems

Annual Reassessment 1Variation Type Ia 1Variation Type Ib 1

Technical (DES) and systemsTrainingChange managementNo SME involvement

Variation Type II 20* Data up to March’10

Drug Information Association www.diahome.org 8

Page 9: European Medicines Agency - diaglobal.org monica buch.pdf · PIM & QRD MONICA BUCHMONICA BUCH Scientific Administrator European Medicines Agency DIA European Regulatory Affairs Forum

PIM Status

Data MigrationCurrent Activity• Conclusion of Data Analysis of all CAPs (SmPC only)

N h t DES i t i t l t dhNo changes to DES, improvement in template adherence• Proof of Concept: Pre-Migration Quality Review

Reduce migration effort by resolving issues earlier• Proof of Concept: Applicant led migration

Confirm: Process; Resource; Guidance• Consolidation and publication of guidance

Planned Activity• Proof of Concept: Agency led migration

Drug Information Association www.diahome.org 9

• Migration timetable

Page 10: European Medicines Agency - diaglobal.org monica buch.pdf · PIM & QRD MONICA BUCHMONICA BUCH Scientific Administrator European Medicines Agency DIA European Regulatory Affairs Forum

Opportunities for MAHs

• Improved compliance with QRD guidance

• Concentration on content rather than format

• Improved quality of product informationConsistency through re-useImproved delivery mechanisms for patients

I d ti• Improved commenting processNot reliant on track changes

I d i t l• Improved version control

• Long-term added value of XML-tagged informationI d i d

Drug Information Association www.diahome.org 10

Improved comparison across products

Page 11: European Medicines Agency - diaglobal.org monica buch.pdf · PIM & QRD MONICA BUCHMONICA BUCH Scientific Administrator European Medicines Agency DIA European Regulatory Affairs Forum

Challenges for MAHs• Learning sufficient information about PIM

Transition from Word based to XML based processes• Transition from Word-based to XML-based processes

• What does the Agency-led migration look like?

• Migration of authorised product informationAligning with QRD and identification and correction of errorsScheduling of migrationsScheduling of migrations

• Maturity of PIM tools and servicesSufficient choice of commercial tools that are well testedRobustness of the Light Authoring Tool

− Will it be the right tool for your company/process?

Sufficient service providers for those MAHs

Drug Information Association www.diahome.org 11

p− Needs to be in place before large-scale migration programme

Page 12: European Medicines Agency - diaglobal.org monica buch.pdf · PIM & QRD MONICA BUCHMONICA BUCH Scientific Administrator European Medicines Agency DIA European Regulatory Affairs Forum

The way forward

EMA committed to PIMEMA committed to PIM(SoI under revision)

Full engagementFull engagement(MoU)

Production useProduction use

Data MigrationData Migration

PIM Extension

Drug Information Association www.diahome.org 12

Page 13: European Medicines Agency - diaglobal.org monica buch.pdf · PIM & QRD MONICA BUCHMONICA BUCH Scientific Administrator European Medicines Agency DIA European Regulatory Affairs Forum

QRD – Overview

• The QRD SecretariatRole & Activities

• The QRD Groupe Q G oupRole, Mandate & Functioning

• Product Information (PI) Quality Review• Product Information (PI) Quality ReviewKey milestonesRevised PIPIT ProcedureRevised PIPIT Procedure

QRD role in PIM

Drug Information Association www.diahome.org 13

Page 14: European Medicines Agency - diaglobal.org monica buch.pdf · PIM & QRD MONICA BUCHMONICA BUCH Scientific Administrator European Medicines Agency DIA European Regulatory Affairs Forum

The QRD Secretariat

• Part of Medical Information (MI) Sector since 2006( )

• Sits in MI Product Information Quality (PIQ) Section since September 2009

PIQ Section covers 3 main areas− Quality Review of Documents (QRD) activities

Mock up & Specimens review− Mock-up & Specimens review− Name Review Group (NRG) activities

• Currently consists of a total of 11 staffCurrently consists of a total of 11 staff6 ADs + 3 AST + 2 AST (int)

Drug Information Association www.diahome.org 14

Page 15: European Medicines Agency - diaglobal.org monica buch.pdf · PIM & QRD MONICA BUCHMONICA BUCH Scientific Administrator European Medicines Agency DIA European Regulatory Affairs Forum

QRD Areas of activity

• Product Information (PI) Quality ReviewProduct Information (PI) Quality Review• Secretariat of the Quality Review of Documents

(QRD) Group( ) p• Product specific or general issues• Legislation, guidance, reference documentsLegislation, guidance, reference documents• User testing• Standard TermsStandard Terms• Active involvement in the PIM Project• Translation services (CdT)

Drug Information Association www.diahome.org 15

• Translation services (CdT)

Page 16: European Medicines Agency - diaglobal.org monica buch.pdf · PIM & QRD MONICA BUCHMONICA BUCH Scientific Administrator European Medicines Agency DIA European Regulatory Affairs Forum

The QRD Group

• QRD Group established in June 1996 to handle linguistic aspects of Product Information

• CompositionpEuropean Medicines Agency (chair & secretariat)Member States (1 Human + 1 Vet)European CommissionEuropean CommissionNorway & Iceland (as observers)Translation Centre (based in Luxembourg)

• Meets at the EMA in plenary meetings 4 times per year

Drug Information Association www.diahome.org 16

Page 17: European Medicines Agency - diaglobal.org monica buch.pdf · PIM & QRD MONICA BUCHMONICA BUCH Scientific Administrator European Medicines Agency DIA European Regulatory Affairs Forum

The QRD Group

QRD mandate (under review)

• To ensure clarity, consistency and accuracy of the medicinal product information and of its t l titranslations

• To verify the terminology used in translations

• To promote legibility of patient information

• To contribute to the development of common understanding on the implementation of legislation and guidelines

Drug Information Association www.diahome.org 17

and guidelines

Page 18: European Medicines Agency - diaglobal.org monica buch.pdf · PIM & QRD MONICA BUCHMONICA BUCH Scientific Administrator European Medicines Agency DIA European Regulatory Affairs Forum

The QRD Group

QRD plenary meetings• Topics for discussion come from legislation, PI ongoing

reviews, external queries, PTLs, MSs, etc.Requests for combined printed PLs (justification + SPC&PL)Requests for combined printed PLs (justification + SPC&PL)Requests for simplification of labelling (art 63 Dir 83/2001)Specific issues with regard to expression of strengthNew standard termsNew standard terms

• Particicipation of PTL + QRD Secr assistance with documentationdocumentation

• Outcome of the topic discussion communicated to applicant by PTL after the meeting minutes are drafted.

Drug Information Association www.diahome.org 18

pp y g

Page 19: European Medicines Agency - diaglobal.org monica buch.pdf · PIM & QRD MONICA BUCHMONICA BUCH Scientific Administrator European Medicines Agency DIA European Regulatory Affairs Forum

PI Quality Review

By Day 120: EN PI undergoes a preliminary “technical” check

Key stages• By Day 120: EN PI undergoes a preliminary “technical” check

(PIQ Technical review) by EMA QRD staff (ensure template compliance, correct location of information, identify issues such as combined PLs expression of strength standard terms linguistic issues etc )PLs, expression of strength, standard terms, linguistic issues, etc.)► Interaction PTL - Applicant

• + Day 121: EN PI reviewed again by EMA QRD staff + MSs QRD y g ymembers + relevant patients’ organisation (only PL)

Day 165 QRD sub-group meeting− At the request of the applicantAt the request of the applicant− Not mandatory; only if major issues need discussion (otherwise, writing/TC)− PTL/PTM meeting chair + EMA QRD Secretariat assistance− 2 MSs QRD members + 2/3 representatives from applicant

Drug Information Association www.diahome.org 19

► Interaction QRD Secretariat (PTL) - Applicant

Page 20: European Medicines Agency - diaglobal.org monica buch.pdf · PIM & QRD MONICA BUCHMONICA BUCH Scientific Administrator European Medicines Agency DIA European Regulatory Affairs Forum

PI Quality Review

Key stages (cont.)

• Right before Opinion: final check of EN PI by EMA QRD Secr to ensure correct implementation of QRD comments► Interaction PTL (QRD Secr) Applicant► Interaction PTL (QRD Secr) - Applicant

• After Opinion: Review of all languages PI by MSs QRD members (with coordination and assistance from QRDmembers (with coordination and assistance from QRD Secr)► Interaction MSs QRD members & QRD Secr - Applicant

Drug Information Association www.diahome.org 20

Page 21: European Medicines Agency - diaglobal.org monica buch.pdf · PIM & QRD MONICA BUCHMONICA BUCH Scientific Administrator European Medicines Agency DIA European Regulatory Affairs Forum

PI Quality Review

Revised PIPIT GuidanceI f V i i l i• Impact of new Variations regulation

No QRD review on the EN PI for any type of Variation (Type IA/IB/II). Only when major changes are introduced, internal decision to be taken.Linguistic review for Type IBs affecting annexes.Grouping and worksharing arrangements.p g g g

• Generics/Hybrids/Biosimilars • EN review only by EMA (pre- and post- D120). For y y (p p )

hybrids/biosimilars normal QRD pre-opinion process to apply (with MSs review).

• EMA proactive role in transmitting final translations of originator to

Drug Information Association www.diahome.org 21

p g ggeneric company.

Page 22: European Medicines Agency - diaglobal.org monica buch.pdf · PIM & QRD MONICA BUCHMONICA BUCH Scientific Administrator European Medicines Agency DIA European Regulatory Affairs Forum

PI Quality Review

Revised PIPIT Guidance (cont.)• D110 PIQ comments sent to applicant as part of Day 120

List of Questions (no longer as a separate set of comments).

• Handling of PI for SMEsEarly coordination with PTL of EN PI assessmentTranslations performed by CdT (except NO/IS)Coordination with EMA SME Office throughout

Drug Information Association www.diahome.org 22

Page 23: European Medicines Agency - diaglobal.org monica buch.pdf · PIM & QRD MONICA BUCHMONICA BUCH Scientific Administrator European Medicines Agency DIA European Regulatory Affairs Forum

QRD role in PIM

• QRD Secretariat part of the PIM DES Team since 2003

• QRD currently represented in most PIM Project Teams(via QRD Secr or QRD MSs)

• Close collaboration with EMA PM Sector with regard to• Close collaboration with EMA PM Sector with regard to the revision of the QRD templates (DES v2.8)

• PIM is a permanent topic in the QRD Plenary meetings p p y gagenda since 2004

• External EMA QRD webpage links to QRD Templates and PIM DES h i d bli ti f QRD t l tPIM DES synchronised publication of QRD templates and DES

• Ongoing EMA discussion on future ownership of DES

Drug Information Association www.diahome.org 23

• Ongoing EMA discussion on future ownership of DES

Page 24: European Medicines Agency - diaglobal.org monica buch.pdf · PIM & QRD MONICA BUCHMONICA BUCH Scientific Administrator European Medicines Agency DIA European Regulatory Affairs Forum

OTHANK YOU

Drug Information Association www.diahome.org 24